We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
MEKTOVI (Pierre Fabre Australia Pty Ltd)
Product name
MEKTOVI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
198 working days (255)
Active ingredients
binimetinib
Registration type
NCE/NBE
Indication
MEKTOVI in combination with BRAFTOVI (encorafenib) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by a validated test.